FDA Sheds New Light On Biosimilars Approval Pathway
The U.S. Food and Drug Administration on Tuesday released its most detailed guidance yet on evidence needed to prove that biosimilars are close matches of their brand-name counterparts, providing more clarity...To view the full article, register now.
Already a subscriber? Click here to view full article